Генерал-директор и финансовый директор Genedrive приобрели по 700 тысяч акций компании

Руководство британской компании Genedrive plc увеличило свои пакеты акций, купив по 700 тысяч обыкновенных акций у каждого из директоров. После сделок Гино Миеле владеет 0,49% капитала, а Расс Шоу — 0,52%.

Перевод ИИ

Текст статьи доступен на языке оригинала.

Нажмите кнопку «Перевести статью» выше, чтобы сгенерировать перевод с помощью ИИ.

Оригинальный контент

Источник

01 September 2026 genedrive plc ("genedrive" or the "Company") Director/PDMR Notification genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company announces that on 28 August 2026, Dr Gino Miele, Chief Executive Officer, acquired 700,000 Ordinary Shares in the Company at a price of 1.38p per share and Russ Shaw, Chief Financial Officer, acquired 700,000 Ordinary Shares in the Company at a price of 1.40p per share. Following these purchases, Dr Gino Miele, is interested in 7,902,187 Ordinary Shares, 0.49% of the issued share capital of the Company and Russ Shaw is interested in 8,400,000 Ordinary Shares, 0.52% of the issued share capital of the Company. Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them. Subscribe to our news alert service: https://investors.genedrive.com/s/efea03 About genedrive plc (http://www.genedrive.com). genedrive plc is a UK-based, commercial-stage pharmacogenetic testing company focused on rapid, point-of-care diagnostic tests to guide safe and effective drug prescription in emergency and acute care settings. genedrive's proprietary technology platform enables clinicians to prescribe safer and more effective therapies based on a patient's genetic profile, supporting improved outcomes while reducing pressure on healthcare systems, lowering downstream healthcare costs through the prevention of avoidable complications and earlier, more effective intervention The Company has two CE-IVD approved and NICE-recommended tests in NHS clinical use. The Genedrive® CYP2C19 ID Kit identifies stroke patients who will not respond to the current standard of care, Clopidogrel, used to reduce risk of secondary stroke. The Genedrive® MT-RNR1 ID Kit helps prevent antibiotic-induced hearing loss (AIHL) in newborns, enabling treatment decisions within actionable timeframes at the point of care. Headquartered in Manchester, genedrive is focused on scaling UK-developed precision diagnostics within routine care and leveraging real-world evidence to support broader international adoption and commercial growth.